Ultrasensitive multiplex assay for detecting rare nucleic acid sequences in biological samples

Rarity Bioscience specializes in advanced molecular detection technologies, particularly through its proprietary superRCA® (super Rolling Circle Amplification) assay. This technology is designed to detect rare nucleic acid sequences, such as mutations associated with cancer, in both liquid biopsy and tissue samples. The superRCA® method boasts exceptional sensitivity, capable of identifying one mutation in a background of 100,000 wild-type DNA molecules. This is achieved through a two-step amplification process that combines standard Rolling Circle Amplification with Padlock Probing, allowing for highly specific and precise genotyping. The assays can analyze multiple targets simultaneously, making them suitable for multiplex applications, and they utilize established flow cytometry for rapid and cost-effective readouts.

In addition to its core technology, Rarity Bioscience offers a range of products and services, including standard and custom assay kits for various mutations across different cancers, such as Acute Myeloid Leukemia and colorectal cancer. The company emphasizes the flexibility of its superRCA® technology, which can be adapted for various sample types, including genomic DNA and circulating tumor DNA (ctDNA). Their assays are designed for research use only and are supported by a dedicated team that assists in assay development and validation, ensuring high sensitivity and efficiency in mutation detection. Rarity Bioscience's commitment to advancing liquid biopsy technology positions it as a leader in the field of molecular diagnostics.

Sweden

Rarity Bioscience provides ultra-sensitive multiplex assays for mutation detection in blood and other liquid biopsies for research, pharma and labs.
 
The superRCA technology is based on padlock probes and rolling circle amplification, enabling extreme sensitivity and specificity, and utilize well established high throughput flow cytometry for the read-out. 

The company was founded in 2021 based on a discovery by Dr Lei Chen, PhD in molecular biology, and a member of Professor Ulf Landegrens team at the Department of Immunology, Genomics and Pathology at Uppsala University.

Rarity Bioscience

Company Details